Neurocrine Biosciences, Inc. presented data from the KINECT-HD study, showcasing significant improvements in chorea across body regions with once-daily INGREZZA capsules in adults with Huntington's disease. This post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium.
The analysis reinforced the primary study findings, demonstrating the consistent benefit of INGREZZA in reducing involuntary movements that can affect any part of the body. Notably, the most significant improvements were observed in the arms and legs, which were the most severely affected at baseline.
These results are meaningful as they illustrate how INGREZZA alleviates chorea symptoms, thereby helping people with Huntington's disease in their everyday lives. The 12-week, Phase 3 KINECT-HD clinical trial previously showed a significant reduction in chorea severity, as measured by the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.